Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: KALETRA

« Back to Dashboard

Kaletra is a drug marketed by Abbvie and is included in three NDAs. It is available from seven suppliers. There are twenty-five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in KALETRA is lopinavir; ritonavir. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. There are six tentative approvals for this compound. Additional details are available on the lopinavir; ritonavir profile page.

Summary for Tradename: KALETRA

Patents:25
Applicants:1
NDAs:3
Suppliers: see list7

Clinical Trials for: KALETRA

Comparison of Liquid Kaletra and Low Dose Kaletra Tablets
Status: Completed Condition: HIV Infections

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers

Lopinavir Capsules to Kaletra or Invirase Tablets
Status: Completed Condition: HIV Infections

KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)
Status: Completed Condition: Antiretroviral Therapy in HIV-1 Infected Children

Lopinavir/Ritonavir (Kaletra) PK in Children
Status: Completed Condition: HIV/AIDS Treatment; HIV Infections

Evaluation of Kaletra Therapy Over the Long-term
Status: Completed Condition: Human Immunodeficiency Virus

GSK706769/KALETRA Drug-drug Interaction Study
Status: Completed Condition: Healthy Subjects; Infection, Human Immunodeficiency Virus

Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
Status: Recruiting Condition: AIDS; Tuberculosis

The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet
Status: Completed Condition: Pregnancy; HIV

Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study
Status: Terminated Condition: HIV

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes6,037,157*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
SOLUTION;ORAL021251Sep 15, 2000RXYes6,911,214*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes5,914,332*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes6,284,767*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes8,025,899*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: KALETRA

Drugname Dosage Strength RLD Submissiondate
lopinavir and ritonavirTablets100 mg/25 mgKaletra12/23/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc